Smith & Nephew rating upgraded to "buy" — 5 things to know

Spinal Tech

Smith & Nephew was upgraded to a "buy" rating by equities research analysts at Goldman Sachs, according to a Dakota Financial News report.

Here are five things to know about the company's stock:

 

•    Goldman Sachs upgraded Smith & Nephew from a "neutral" rating.
•    Smith & Nephew has a one-year low of $28.87 and a one-year high of $40.38.
•    The stock's 50-day moving average is $35 and its 200-day moving average is $34.
•    The company has a market cap of $15.32 billion.
•    Currently, the stock has an average rating of "hold" and an average price target of $63.30.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers